Henrik Kjaer Hansen
Director/Board Member chez WCG CLINICAL, INC.
Profil
Henrik Kjaer Hansen is currently the Director at Sonion A since 2022 and the Independent Director at WCG Clinical, Inc. since 2020.
He is also the Senior Partner at Novo Principal Investments and the Senior Partner & Head of Principal Investments at Novo Holdings A, both since 2017.
Previously, he served as the Independent Director at Orexo AB from 2018 to 2023.
He also held positions as a Director at Xellia Pharmaceuticals AS and as a Senior Vice President at Moelis & Co. (UK) LLP.
Mr. Hansen completed his undergraduate and graduate degrees at Copenhagen Business School.
Postes actifs de Henrik Kjaer Hansen
| Sociétés | Poste | Début |
|---|---|---|
| WCG CLINICAL, INC. | Director/Board Member | 01/01/2020 |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Chief Investment Officer | 01/12/2017 |
Novo Principal Investments
 Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01/01/2017 |
Sonion A/S
 Sonion A/S Medical SpecialtiesHealth Technology Sonion A/S design and manufactures micro-acoustic and micro-mechanical components for hearing instruments, in-ear earphones and earphones. The firm offers products such as receivers, microphones, noise cancelling microphone, boom microphones, vibration sensors, active telecoils, passive telecoils, bone conduction vibrator, volume controls, switches, connector systems, trimmers, faceplates, tapers, and socketm, combination units and sonion sound dampers. The company was founded by Jorgen Weber Jensen and Jens-Jorn Stockholm in 1974 and is headquartered in Roskilde, Denmark. | Director/Board Member | 10/05/2022 |
Anciens postes connus de Henrik Kjaer Hansen
| Sociétés | Poste | Fin |
|---|---|---|
| OREXO AB | Director/Board Member | 27/10/2023 |
Xellia Pharmaceuticals AS
 Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Director/Board Member | - |
Moelis & Co. (UK) LLP
 Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The private company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010. | Corporate Officer/Principal | - |
Formation de Henrik Kjaer Hansen
| Copenhagen Business School | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OREXO AB | Health Technology |
| Entreprise privées | 6 |
|---|---|
Xellia Pharmaceuticals AS
Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Health Technology |
Sonion A/S
Sonion A/S Medical SpecialtiesHealth Technology Sonion A/S design and manufactures micro-acoustic and micro-mechanical components for hearing instruments, in-ear earphones and earphones. The firm offers products such as receivers, microphones, noise cancelling microphone, boom microphones, vibration sensors, active telecoils, passive telecoils, bone conduction vibrator, volume controls, switches, connector systems, trimmers, faceplates, tapers, and socketm, combination units and sonion sound dampers. The company was founded by Jorgen Weber Jensen and Jens-Jorn Stockholm in 1974 and is headquartered in Roskilde, Denmark. | Health Technology |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Moelis & Co. (UK) LLP
Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The private company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010. | Finance |
Novo Holdings A/S (Investment Company)
Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Finance |
WCG Clinical, Inc.
 WCG Clinical, Inc. BiotechnologyHealth Technology WCG Clinical, Inc. provides clinical trial solutions, which focus on providing solutions that are designed to measurably improve the quality and efficiency of clinical research, stimulate growth and foster compliance. It transformational solutions enable biopharmaceutical companies, contract research organizations, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human protection. The company was founded in 2012 and is headquartered in Princeton, NJ. | Health Technology |
